Document Detail


Long-term prognosis of nonalcoholic fatty liver disease: is pharmacological therapy actually necessary?
MedLine Citation:
PMID:  16706829     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD) comprises a wide spectrum of liver injury, ranging from steatosis and steatohepatitis to cirrhosis. Reasons for the different natural course in individuals with NAFLD are still unclear. The aim of this study was to describe the natural course of disease in individuals with NAFLD who did not receive pharmacological therapy. METHODS: A total of 27 individuals with NAFLD (male/female ratio: 10/17, mean age 49.7 years) were prospectively enrolled. Management after diagnosis consisted of establishment of an appropriate diet and exercise (walking and jogging) program, treatment of associated metabolic conditions such as diabetes and dyslipidemia, and discontinuation of potentially hepatotoxic drugs if the patient was taking these. Liver tests were performed at diagnosis and at 3-month intervals during the follow-up period. Mean follow-up period was 43.3 months (range 36-49 months). RESULTS: From baseline to the end of the follow-up period, although there was no significant difference observed in terms of the mean body mass index, serum aminotransferase levels significantly improved (48.8+/-29.9 U/L to 31.6+/-16.0 U/L for aspartate aminotransferase [AST] and 66.3+/-38.3 U/L to 39.6+/-22.9 U/L for alanine aminotransferase [ALT]; P<0.05). No significant differences in platelet counts, serum albumin level or prothrombin time were observed (P>0.05). No patient developed signs of advanced liver disease during the follow-up period. CONCLUSION: A treatment strategy comprising diet, exercise and management of associated metabolic conditions is associated with improvement in aminotransferases among patients with NAFLD. Further investigation is needed to examine the long-term efficacy of this approach on liver histology and clinical outcomes.
Authors:
Kubilay Cinar; Sahin Coban; Ramazan Idilman; Ali Tuzun; Mustafa Sarioglu; Mehmet Bektas; Esra Erden; Hakan Bozkaya; Ali Ozden
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of gastroenterology and hepatology     Volume:  21     ISSN:  0815-9319     ISO Abbreviation:  J. Gastroenterol. Hepatol.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-05-18     Completed Date:  2007-08-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8607909     Medline TA:  J Gastroenterol Hepatol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  169-73     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. cinar@medicine.ankara.edu.tr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alanine Transaminase / blood
Aspartate Aminotransferases / blood
Diet Therapy*
Disease Progression
Exercise Therapy*
Fatty Liver / blood,  therapy*
Female
Humans
Male
Middle Aged
Prognosis
Prospective Studies
Time Factors
Chemical
Reg. No./Substance:
EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase
Comments/Corrections
Comment In:
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):14   [PMID:  16706805 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma.
Next Document:  Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor nec...